A stereoselective three‐component reaction: One‐pot synthesis of cis‐isoquinolonic acids catalyzed by silica sulfuric acid under mild and heterogeneous conditions

A mild and stereoselective three‐component one‐step synthesis of cis‐isoquinolonic acid using silica sulfuric acid as a heterogeneous catalyst from an aldehyde, amine and homophthalic anhydride in acetonitrile is described. This new method produces pure products in high yields (81‐91%).     

Nanocrystalline magnesium oxide: a novel and efficient catalyst for facile synthesis of 2,4,5-trisubstituted imidazole derivatives

Abstract  

Nanocrystalline magnesium oxide with high specific surface area has been used as a novel and efficient catalyst for an improved and rapid synthesis of biologically active 2,4,5-trisubstituted imidazoles, by three-component, one-pot condensation of 1,2-diketones and aryl aldehydes, in excellent yields under solvent-free and conventional heating conditions. The method has several advantages, for example excellent yields, shorter reaction time, and use of a non-toxic and recyclable catalyst.     

Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B

Gilteritinib, an FDA-approved tyrosine kinase inhibitor approved for the treatment of relapsed/refractory FLT3-mutated acute myeloid leukemia, is primarily eliminated via CYP3A4-mediated metabolism, a pathway that is sensitive to the co-administration of known CYP3A4 inhibitors, such as itraconazole. However, the precise mechanism by which itraconazole and other CYP3A-modulating drugs affect the absorption and disposition of gilteritinib remains unclear. In the present investigation, we demonstrate that pretreatment with itraconazole is associated with a significant increase in the systemic exposure to gilteritinib in mice, recapitulating the observed clinical drug–drug interaction. However, the plasma levels of gilteritinib were only modestly increased in CYP3A-deficient mice and not further influenced by itraconazole. Ensuing in vitro and in vivo studies revealed that gilteritinib is a transported substrate of OATP1B-type transporters, that gilteritinib exposure is increased in mice with OATP1B2 deficiency, and that the ability of itraconazole to inhibit OATP1B-type transport in vivo is contingent on its metabolism by CYP3A isoforms. These findings provide new insight into the pharmacokinetic properties of gilteritinib and into the molecular mechanisms underlying drug–drug interactions with itraconazole.